26 trials changed in the last 30 days: 0 stopped, 6 with notable changes, 20 with minor changes only.
Primary completion pushed from Dec 10, 2028 to Jul 8, 2030
Also in this update: Primary endpoint(s) modified; Study completion pushed from Dec 21, 2029 to Jul 8, 2030
Regeneron PharmaceuticalsPhase 3 NCT07559513 Registry history of NCT07559513 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Mar 25, 2027 to Nov 8, 2028
Also in this update: Study completion pushed from Nov 30, 2027 to Nov 8, 2028
Regeneron PharmaceuticalsPhase 1/2 NCT04590326 Registry history of NCT04590326 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Regeneron PharmaceuticalsPhase 4 NCT07587658 Registry history of NCT07587658 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Regeneron PharmaceuticalsPhase 3 NCT07697599 Registry history of NCT07697599 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Primary completion pushed from Jul 25, 2029 to Sep 14, 2029; Study completion pushed from Oct 16, 2029 to Dec 6, 2029
Regeneron PharmaceuticalsPhase 1/2 NCT07675824 Registry history of NCT07675824 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Regeneron PharmaceuticalsPhase 1 NCT07759167 Registry history of NCT07759167 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Regeneron PharmaceuticalsPhase 2 NCT07477704 Registry history of NCT07477704 on ClinicalTrials.gov (opens the registry)
Trial completed
Regeneron PharmaceuticalsPhase 1 NCT06669234 Registry history of NCT06669234 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Jan 21, 2027 to Apr 13, 2026; Final enrollment: 12343 participants (planned 3930)
Regeneron PharmaceuticalsNot specified NCT03936335 Registry history of NCT03936335 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 20, 2027 to Jan 28, 2028
Also in this update: Study completion pushed from Dec 8, 2027 to May 17, 2028
Regeneron PharmaceuticalsPhase 2 NCT07235917 Registry history of NCT07235917 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jan 6, 2027 to May 5, 2027
Regeneron PharmaceuticalsPhase 1 NCT05259709 Registry history of NCT05259709 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 35 → 44 locations
Regeneron PharmaceuticalsPhase 3 NCT07430956 Registry history of NCT07430956 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 225 → 231 locations
Regeneron PharmaceuticalsPhase 3 NCT06541704 Registry history of NCT06541704 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 20 → 23 locations
Regeneron PharmaceuticalsPhase 3 NCT07410117 Registry history of NCT07410117 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 18 → 21 locations
And 1 more change in the last 30 days
Regeneron PharmaceuticalsPhase 2 NCT07685808 Registry history of NCT07685808 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 46 → 49 locations
And 1 more change in the last 30 days
Regeneron PharmaceuticalsPhase 3 NCT07213778 Registry history of NCT07213778 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 34 → 45 locations
Regeneron PharmaceuticalsPhase 3 NCT07626411 Registry history of NCT07626411 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 28 → 39 locations
And 1 more change in the last 30 days
Regeneron PharmaceuticalsPhase 3 NCT07222761 Registry history of NCT07222761 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 84 → 87 locations
And 1 more change in the last 30 days
Regeneron PharmaceuticalsPhase 2 NCT07175428 Registry history of NCT07175428 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 190 → 194 locations
And 1 more change in the last 30 days
Regeneron PharmaceuticalsPhase 3 NCT06091865 Registry history of NCT06091865 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 6 → 12 locations
Regeneron PharmaceuticalsPhase 3 NCT07493304 Registry history of NCT07493304 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 17 → 20 locations
Regeneron PharmaceuticalsPhase 3 NCT07318610 Registry history of NCT07318610 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 14 → 19 locations
Regeneron PharmaceuticalsPhase 3 NCT07393282 Registry history of NCT07393282 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 6 → 9 locations
Regeneron PharmaceuticalsPhase 2 NCT07527910 Registry history of NCT07527910 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 1 → 5 locations
Regeneron PharmaceuticalsPhase 1 NCT07527923 Registry history of NCT07527923 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Mar 30, 2027 to Jul 28, 2027
Regeneron PharmaceuticalsNot specified NCT03428646 Registry history of NCT03428646 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-15 | NCT07876492 A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult… | Phase 3 | Not Yet Recruiting |
| 2026-10-15 | NCT07876505 Healthy Adult Participants Trial Comparing Different Cenvacibart Presentations | Phase 1 | Not Yet Recruiting |
| 2026-10-07 | NCT07863024 Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving… | Phase 1/2 | Not Yet Recruiting |
| 2026-10-06 | NCT07861152 Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants… | Phase 1 | Not Yet Recruiting |
| 2026-10-02 | NCT07854782 Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic… | Phase 3 | Not Yet Recruiting |
| 2026-09-30 | NCT07850921 REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant… | Phase 1/2 | Not Yet Recruiting |
| 2026-09-22 | NCT07832370 A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD) | Phase 1/2 | Not Yet Recruiting |
| 2026-09-21 | NCT07830329 Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe… | Phase 2 | Not Yet Recruiting |
| Phase 1 | 18 | |
| Phase 1/2 | 25 | |
| Phase 2 | 27 | |
| Phase 2/3 | 2 | |
| Phase 3 | 36 | |
| Phase 4 | 4 |
Multiple Myeloma (12) · Lung Cancer (11) · Non-Small Cell Lung Cancer (NSCLC) (11) · Obesity (9) · Melanoma (7) · Non-Hodgkin Lymphoma (7) · NASH / MASH (6) · Prostate Cancer (5) · Chronic Kidney Disease (4) · Follicular Lymphoma (4)